Boosting Sensitivity through a Multianalyte Cerebrospinal Fluid Approach for Diagnosis, Prognostication, and Immune Monitoring for Brain Tumors

IF 33.3 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2025-10-06 DOI:10.1158/2159-8290.cd-25-1162

Hannah K. Weiss, Camila S. Fang, Daniel A. Orringer, Alexandra M. Miller

引用次数: 0

Abstract

Summary: The CSF-BAM assay, developed by Pearlman, Wang, and colleagues, integrates the detection of somatic mutations, genome aneuploidy, and B- and T-cell receptor clonality from a single cerebrospinal fluid DNA library to increase the sensitivity of cerebrospinal fluid to diagnosis and track brain tumors. See related article by Pearlman et al., p. 2002

查看原文本刊更多论文

通过多分析物脑脊液方法提高脑肿瘤诊断、预测和免疫监测的敏感性

摘要：由Pearlman、Wang及其同事开发的CSF-BAM检测，整合了单个脑脊液DNA文库中体细胞突变、基因组非整倍体、B细胞和t细胞受体克隆的检测，以提高脑脊液诊断和跟踪脑肿瘤的敏感性。参见相关文章，由Pearlman等人，p. 2002

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.